Intelligence / Healthtech / New Clinical Trials / Hanmi Pharmaceutical Company Limited
Hanmi Pharmaceutical Company Limited
27 Oct 2026: Trial registered · A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 27 Oct 2026
- Title
- A Study to Evaluate Efficacy and Safety of HIP2602 in Erectile Dysfunction Patients
- Conditions
- Erectile Dysfunction
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- South Korea
- Country
- South Korea
- Reference
- NCT07899073
- Location
- South Korea
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Hanmi Pharmaceutical Company Limited
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Hanmi Pharmaceutical Company Limited in our registers.
More from South Korea
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.